Eli Lilly Stock Slumps on Lowered Sales Forecast
1. Eli Lilly lowered 2024 revenue forecast to $45 billion from previous estimates. 2. Slower than expected sales of weight-loss drugs Mounjaro and Zepbound. 3. CEO expects 60% increase in drug production in early 2025. 4. Analysts projected $45.48 billion, but Eli Lilly anticipates lower sales. 5. Despite recent drops, Eli Lilly remains up over 17% year-over-year.